2025 年指導
葛蘭素史克提供了固定匯率 (CER) 下的全年指導。

• 預計營業額增長3％至5％
• 預計核心營業利潤增長6％至8％
• 預計核心每股收益增長6％至8％

此指導的支持來自以下2025年全年固定匯率 (CER) 下的營業額預期：

• 專業藥品：預計營業額將低雙位數百分比增長
• 疫苗：預計營業額將低單位數百分比下降
• 普通藥品：預計營業額基本保持穩定

以上內容來自Benzinga Earnings專欄，原文如下：

2025 Guidance 

GSK provides its full-year guidance at constant exchange rates (CER). 

• Turnover is expected to increase between 3 to 5 per cent 
• Core operating profit is expected to increase between 6 to 8 per cent 
• Core earnings per share is expected to increase between 6 to 8 per cent 

This guidance is supported by the following turnover expectations for full-year 2025 at CER 

• Specialty Medicines – expected increase of a low double-digit per cent in turnover 
• Vaccines – expected decrease of a low single-digit per cent in turnover 
• General Medicines – expected to be broadly stable for turnover